Inoue Y, Katayama N, Yoshioka N, Yoshikawa K, Kashima M, Shimizu T, Tsukune Y, Ohtomo K
Department of Radiology, Institute of Medical Science, University of Tokyo, Japan.
Ann Nucl Med. 1999 Dec;13(6):453-6. doi: 10.1007/BF03164944.
The aim of this study was to evaluate breast parenchymal activity on scintimammography with bone-seeking agents and 99mTc-MIBI. Scintimammography was performed with bone-seeking agents in 61 patients and with 99mTc-MIBI in 33 patients. Activity in the breast parenchyma contralateral to the suspected lesion was visually assessed by two independent observers. Increased breast parenchymal activity was shown in 19 of 61 patients examined with bone-seeking agents, while it was demonstrated in only two of 33 patients examined with 99mTc-MIBI. Breast parenchymal activity of bone-seeking agents was higher in patients aged 50 years or younger than in those older than 50. Increased parenchymal activity of bone-seeking agents may disturb visualization of primary breast cancer especially in relatively young patients. Low parenchymal activity is suggested to be a favorable characteristic of 99mTc-MIBI as a scintimammographic agent.
本研究的目的是利用亲骨性放射性药物和99mTc-MIBI评估乳腺闪烁造影术中的乳腺实质活性。61例患者接受了亲骨性放射性药物乳腺闪烁造影，33例患者接受了99mTc-MIBI乳腺闪烁造影。两名独立观察者对疑似病变对侧乳腺实质的活性进行了视觉评估。在61例接受亲骨性放射性药物检查的患者中，有19例显示乳腺实质活性增加，而在33例接受99mTc-MIBI检查的患者中，只有2例显示活性增加。50岁及以下患者的亲骨性放射性药物的乳腺实质活性高于50岁以上患者。亲骨性放射性药物的实质活性增加可能会干扰原发性乳腺癌的显像，尤其是在相对年轻的患者中。低实质活性被认为是99mTc-MIBI作为乳腺闪烁造影剂的一个有利特征。
